Manufactures pharmaceutical products and recently commenced operations in Kenya. Facilities received a WHO inspection closure report, indicating compliance with WHO manufacturing standards, and reportedly use 55 to 60 percent renewable energy. For FY26, the company reported revenue of Rs 927.11 crore with an EBITDA margin of 25.36 percent. The cost structure is materials-heavy at 41.7 percent of revenue, followed by other operating expenses at 21.7 percent and employee costs at 14.7 percent. A leadership transition took effect in July 2026, with Mr. Rahul Adakmol, previously at Dr. Reddy's, Bharat Serums and Reliance, appointed CEO from July 15, 2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals. Pharmaceutical manufacturer
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 747 | 752 | 770 | 810 | 927 |
| EBITDA (ex other income) | 45 | 117 | 121 | 127 | 162 |
| margin % | 6.0 | 15.6 | 15.8 | 15.6 | 17.4 |
| Owners' profit | 15 | 71 | 75 | 84 | 129 |
| EPS, as reported (₹) | 1.46 | 6.83 | 7.23 | 8.02 | 12.23 |
| ROE % · ROCE % | 2.7 · 6.7 | 8.4 · 12.1 | 8.1 · 11.7 | 8.3 · 11.8 | 10.9 · 16.0 |
| Debt / equity (x) | 0.12 | 0.11 | 0.09 | 0.07 | 0.00 |
| Cash from operations | 135 | 34 | 152 | 106 | 139 |
| Capex | 0 | (94) | (28) | (76) | (57) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Profit before tax | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Net profit | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS (₹) | 2.31 | 2.27 | 1.47 | 4.08 | 2.58 | 2.20 | 3.37 | 4.73 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Bliss GVS Pharma allots 55,250 shares under ESOP 2019 | capital market events | low | — | — |
| 2 Sept 2026 · Post-offer ad filed for Bliss GVS Pharma open offer by Anupam Rasayan | strategic transactions | high | — | — |
| 25 Aug 2026 · SEBI extends special window for re-lodging physical share transfers | compliance | minimal | — | — |
| 21 Aug 2026 · Postal Ballot Notice: Appointment of Mr. Santosh Parab as Director | compliance | minimal | — | — |
| 20 Aug 2026 · Postal ballot to appoint Mr. Santosh Parab as Non-Executive Director | management changes | medium | — | — |
| 14 Aug 2026 · Bliss GVS Pharma Q1 FY27: Standalone net profit up 83 percent YoY | compliance | minimal | — | — |
| 12 Aug 2026 · Bliss GVS Pharma grants 3.2 lakh stock options to employees under ESOP 2019 | business updates | medium | — | — |
| 12 Aug 2026 · Q1 FY27 results strong YoY; new non-executive director proposed | management changes | medium | — | — |
| 11 Aug 2026 · ESOP 2019: Bliss GVS allots 31,250 shares at Rs 43 each to employees | capital market events | low | — | — |
| 11 Aug 2026 · LIC cuts Bliss GVS Pharma stake from 5.11 percent to 2.96 percent via market sale | ownership changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 56.0 | 28.9 | 132 of 169 | 22% |
| P/B | 6.2 | 3.3 | 130 of 163 | 20% |
| ROCE | 15.1 | 10.8 | 63 of 183 | 66% |
| ROE | 10.9 | 10.4 | 82 of 171 | 52% |
| Debt / Equity | 0.0 | 0.1 | 44 of 171 | 75% |
| EBITDA margin | 30.1 | 17.5 | 34 of 165 | 80% |
| Revenue growth | 37.6 | 16.3 | 31 of 161 | 81% |
| Profit growth | 15.8 | 30.9 | 92 of 158 | 42% |
| Market cap | 7647 | 839 | 47 of 182 | 75% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
